- Oops!Something went wrong.Please try again later.
SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- GoodRx (NASDAQ: GDRX), America’s leading resource for healthcare savings, today announced that it has entered into an agreement with Surescripts, the nation’s leading health information network, to deliver drug discount price information to prescribers using Surescripts Real-Time Prescription Benefit when prescribing medications for uninsured patients and patients whose price information isn’t already available from their PBM or health plan. Surescripts Real-Time Prescription Benefit delivers cost information in the electronic workflow so prescribers can make more informed decisions and address patient prescription cost concerns at the point of care.
Approximately one-third of Americans say they have skipped filling a prescription for a chronic condition one or more times because of the cost, according to an internal GoodRx survey. By improving price transparency at the point of care, prescribers can have more informed conversations with their patients and ensure they can afford the treatment they need before getting to the pharmacy counter. With this new integration, prescribers using Surescripts Real-Time Prescription Benefit will be able to provide uninsured patients and patients whose price information isn’t already available from their PBM or health plan with drug discount pricing from GoodRx, which provides savings of up to 80% from pharmacy retail prices on prescriptions, so patients can make more educated decisions about their care.
“We are always looking for ways to increase prescription price transparency and affordability for more Americans, so we are excited to work with Surescripts to arm prescribers with the tools and information they need to choose medications that are both accessible and clinically appropriate,” said Doug Hirsch, co-CEO and co-founder of GoodRx.
Surescripts is a nationwide network that connects virtually all electronic health records software vendors (EHRs), pharmacies and health systems, enabling providers to view patient-specific benefit and cost information and then electronically prescribe a medication. Last year, nearly 2 billion electronic prescriptions were delivered through Surescripts. Integrating GoodRx pricing will support getting cost information into the hands of patients.
“Providing prescription price transparency at the point of care is critical to improving medication adherence and ensuring patients can receive the treatment they need,” said Mike Pritts, Chief Product Officer, at Surescripts. “With the addition of our drug discount pricing feature for uninsured patients as well as patients whose price information isn’t already available from their PBM or health plan, Real-Time Prescription Benefit arms prescribers with more of the information they need, so they can have meaningful cost conversations and get patients started on medication they can access and afford.”
To learn more about GoodRx, visit goodrx.com.
GoodRx helps Americans get the healthcare they need at a price they can afford. As America’s leading resource for healthcare savings, GoodRx connects consumers with affordable and convenient prescriptions and medical care, including telehealth, mail order prescriptions, doctor visits, and lab tests. We have helped Americans save over $30 billion since 2011 and are one of the most downloaded medical apps over the past decade.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding consumer savings, the availability and use of GoodRx pricing in the Surescripts product and benefits and use of GoodRx pricing by Surescripts providers and patients. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our acquisition strategy, the integration of acquired business and the important factors discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2020, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.